Teacher Retirement System of Texas Sells 1,129 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Teacher Retirement System of Texas reduced its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 9.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 10,462 shares of the company’s stock after selling 1,129 shares during the period. Teacher Retirement System of Texas’ holdings in ARS Pharmaceuticals were worth $132,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC grew its holdings in shares of ARS Pharmaceuticals by 7.1% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 368,556 shares of the company’s stock worth $4,636,000 after purchasing an additional 24,385 shares in the last quarter. Wells Fargo & Company MN raised its position in ARS Pharmaceuticals by 47.1% in the 4th quarter. Wells Fargo & Company MN now owns 41,701 shares of the company’s stock valued at $440,000 after purchasing an additional 13,361 shares during the last quarter. Oppenheimer & Co. Inc. bought a new position in ARS Pharmaceuticals in the 1st quarter valued at $189,000. Vanguard Group Inc. raised its position in ARS Pharmaceuticals by 3.5% in the 4th quarter. Vanguard Group Inc. now owns 3,464,952 shares of the company’s stock valued at $36,555,000 after purchasing an additional 115,656 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its position in shares of ARS Pharmaceuticals by 4.6% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 60,294 shares of the company’s stock worth $636,000 after acquiring an additional 2,670 shares during the last quarter. 68.16% of the stock is owned by institutional investors.

Insider Activity at ARS Pharmaceuticals

In related news, insider Eric Karas sold 15,000 shares of the stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $16.99, for a total transaction of $254,850.00. Following the completion of the transaction, the insider directly owned 10,315 shares of the company’s stock, valued at approximately $175,251.85. This represents a 59.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Brent L. Saunders sold 120,000 shares of the stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $14.25, for a total value of $1,710,000.00. The disclosure for this sale can be found here. Insiders sold 1,043,118 shares of company stock valued at $18,024,863 over the last ninety days. Company insiders own 33.50% of the company’s stock.

ARS Pharmaceuticals Stock Down 2.3%

NASDAQ:SPRY opened at $17.92 on Monday. ARS Pharmaceuticals, Inc. has a 1 year low of $8.91 and a 1 year high of $18.90. The company has a current ratio of 11.00, a quick ratio of 10.74 and a debt-to-equity ratio of 0.30. The stock has a market cap of $1.76 billion, a price-to-earnings ratio of -111.99 and a beta of 0.90. The stock has a 50-day moving average price of $15.61 and a two-hundred day moving average price of $13.68.

ARS Pharmaceuticals (NASDAQ:SPRY) last posted its earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.35). The firm had revenue of $7.97 million during the quarter, compared to analysts’ expectations of $7.48 million. ARS Pharmaceuticals had a negative return on equity of 6.94% and a negative net margin of 16.11%. As a group, equities analysts expect that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded ARS Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, June 28th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $31.00.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.